Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Director/PDMR Shareholding

12 Dec 2006 18:33

ReGen Therapeutics PLC12 December 2006 Notification of Change in Interests of Directors London: On 12 December 2006 options ("Options") were granted to directors of theCompany in respect of an aggregate of 43,200,000 ordinary shares of 0.1p each inthe Company ("Ordinary Shares"). The Options, taken with existing options andwarrants over Ordinary Shares, will, if exercised, represent 5.77 per cent ofthe then enlarged issued share capital of the Company. All Options were granted with an exercise price of 1.25p per Ordinary Share (theclosing mid-market price on 12 December 2006) and may normally be exercisedbetween 31 December 2007 and 12 December 2016. The exercise of all Options issubject to first meeting performance conditions based on product launch andachieving certain revenue and profit targets over 2007, 2008 and 2009. Prior toreceiving these grants the executive Directors cancelled all previously grantedoptions (which were not subject to performance targets). No amounts were paid for the grants themselves. Percy Lomax was granted 13,000,000 Options. Following this announcement Mr Lomaxholds a total of 2,282,069 Ordinary Shares (representing 0.33 per cent of issuedshare capital) and 13,000,000 options over Ordinary Shares in the capital of theCompany. Timothy Shilton was granted 9,000,000 Options. Following this announcement MrShilton holds a total of 500,000 Ordinary Shares (representing 0.07 per cent ofissued share capital) and 9,000,000 options over Ordinary Shares in the capitalof the Company. Norman Lott was granted 8,000,000 Options. Following this announcement Mr Lottholds a total of 182,000 Ordinary Shares (representing 0.026 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Martin Small was granted 8,000,000 Options. Following this announcement Mr Smallholds a total of 2,248,736 Ordinary Shares (representing 0.32 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Keith Corbin was granted 2,700,000 Options. Following this announcement MrCorbin holds a total of 1,105,000 Ordinary Shares (representing 0.16 per cent ofissued share capital) and 3,300,000 options over Ordinary Shares in the capitalof the Company. Peter Garrod was granted 2,500,000 Options. Following this announcement MrGarrod holds a total of 66,750,000 Ordinary Shares (representing 9.61 per centof issued share capital) and 2,500,000 options over Ordinary Shares in thecapital of the Company. Further Information Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Sep 20207:00 amRNSClinical Study with Nasally Administered Foralumab
16th Sep 20209:05 amRNSSecond Price Monitoring Extn
16th Sep 20209:00 amRNSPrice Monitoring Extension
16th Sep 20207:00 amRNSDemerger of StemPrintER and Distribution in Specie
7th Sep 202011:05 amRNSSecond Price Monitoring Extn
7th Sep 202011:00 amRNSPrice Monitoring Extension
2nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20204:35 pmRNSPrice Monitoring Extension
2nd Sep 20202:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20202:00 pmRNSPrice Monitoring Extension
28th Aug 202012:04 pmRNSHolding(s) in Company
28th Aug 202010:30 amRNSADS Registration Statement Filing Clarification
27th Aug 20204:00 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20207:00 amRNSTiziana CEO Interview
26th Aug 20207:00 amRNSGrant of Options - Director Dealings
24th Aug 20207:00 amRNSPatent Granted for Anti-IL-6/IL-6
21st Aug 20207:00 amRNSPatent Granted for Milciclib
20th Aug 20207:00 amRNSUpdate - Scientific Advisory Board
18th Aug 20209:05 amRNSSecond Price Monitoring Extn
18th Aug 20209:00 amRNSPrice Monitoring Extension
18th Aug 20207:00 amRNSPatent Granted for Foralumab
11th Aug 20208:49 amRNSBTIG's Virtual Biotechnology Conference
10th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20204:00 pmRNSClosing of $57.25 Million Offering
4th Aug 20207:00 amRNSExpedited Clinical Development Plan
3rd Aug 20207:00 amRNSIssue of Equity
31st Jul 20205:00 pmRNSTotal Voting Rights
31st Jul 20204:41 pmRNSSecond Price Monitoring Extn
31st Jul 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20207:00 amRNSSubmission of a Patent Application for Foralumab
30th Jul 20204:30 pmRNSProposed Admission to the Official List
30th Jul 202011:53 amRNSUpdate on Timings and Corporate Actions
30th Jul 20207:00 amRNSInvestor Webinar to Provide Corporate Updates
29th Jul 20202:05 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
24th Jul 20207:00 amRNSExercise of Warrants and Issue of Equity
20th Jul 20202:51 pmRNSDirector Appointment
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
16th Jul 202011:39 amRNSResult of AGM
16th Jul 20207:00 amRNSSubmission of Patent Application
15th Jul 20204:29 pmRNSChange to ADS Ratio - Updated
15th Jul 20201:00 pmRNSChange to ADS Ratio
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:41 pmRNSSecond Price Monitoring Extn
13th Jul 20204:36 pmRNSPrice Monitoring Extension
10th Jul 20206:01 pmRNSInterview to Air on Bloomberg International
1st Jul 20207:00 amRNSTotal Voting Rights and StemPrintER Update
29th Jun 202011:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.